Alkermes (NASDAQ:ALKS) had its target price boosted by Mizuho from $24.00 to $28.00 in a research report report published on Thursday morning, The Fly reports.
Several other equities analysts have also recently commented on the stock. Bank of America dropped their target price on shares of Alkermes from $21.00 to $19.00 and set a neutral rating on the stock in a research report on Wednesday, September 30th. BidaskClub cut shares of Alkermes from a hold rating to a sell rating in a report on Thursday, December 31st. JPMorgan Chase & Co. reaffirmed a hold rating on shares of Alkermes in a report on Wednesday, October 7th. TheStreet raised shares of Alkermes from a d+ rating to a c rating in a report on Wednesday, December 2nd. Finally, ValuEngine cut shares of Alkermes from a hold rating to a sell rating in a report on Saturday, October 31st. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $21.09.
Alkermes stock opened at $20.38 on Thursday. Alkermes has a 52 week low of $11.98 and a 52 week high of $22.22. The company’s 50 day moving average price is $19.98 and its two-hundred day moving average price is $18.33. The company has a quick ratio of 2.39, a current ratio of 2.71 and a debt-to-equity ratio of 0.25. The stock has a market cap of $3.24 billion, a P/E ratio of -44.30, a P/E/G ratio of 11.39 and a beta of 1.25.
Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, October 29th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.40. Alkermes had a negative net margin of 6.28% and a positive return on equity of 9.35%. The firm had revenue of $265.00 million for the quarter, compared to analysts’ expectations of $238.39 million. During the same quarter last year, the firm earned ($0.04) EPS. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities analysts anticipate that Alkermes will post -0.16 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new position in Alkermes in the 3rd quarter valued at approximately $2,064,000. BNP Paribas Arbitrage SA grew its position in shares of Alkermes by 163.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 187,287 shares of the company’s stock valued at $3,103,000 after purchasing an additional 116,170 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Alkermes by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 15,418,310 shares of the company’s stock valued at $299,193,000 after purchasing an additional 166,782 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Alkermes by 330.0% during the 2nd quarter. Principal Financial Group Inc. now owns 172,954 shares of the company’s stock valued at $3,356,000 after purchasing an additional 132,733 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Alkermes during the 3rd quarter valued at $2,648,000. Institutional investors and hedge funds own 97.87% of the company’s stock.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
Featured Article: Hedge Funds Explained
